|
|
- Bernard Marsh
- 5 years ago
- Views:
Transcription
1 MEETING PROSPECTUS
2 CONTENT Introduction... 3 Workshop description... 4 Background...4 Meeting Objectives...4 Learning Objectives...4 Format...4 Unique Meeting Features...4 Target audience...5 Demographics...5 Geographical distribution last meeting...5 Program Committee... 6 Participants Feedback Personal benefits...7 Content...7 Lectures...8 Metrics Pre-workshop communications...10 Post-workshop communications...10 Most effective elements...11 Quotes...11 Summary
3 INTRODUCTION The Workshop on HCV Therapy Advances was initiated three years ago and has been designed to educate treating physicians and researchers on the latest developments in the field of hepatitis treatment and the promising new treatment possibilities of new direct antivirals that are becoming available. The meeting is intended as a platform for sharing data and discussing the clinical application of these new antivirals in an interactive setting. The conference presentations by international key opinion leaders are focused on the translation of the latest scientific data and availability of new drugs into daily clinical practice. Clinical case discussions are also an important part of the program, in order to stimulate interaction and allow discussions on local issues. This meeting prospectus is designed in order to provide information on the meeting set up, demographics and metrics and also on the evaluation scores from the 2013 workshop participants. We hope this information is of interest. Please contact us if specific information is missing and we will gladly provide you with additional documentation. We would surely welcome your suggestions for improvement of this workshop in order to best serve the Hepatitis treating community in Europe. On behalf of the Program Committee, STEFAN ZEUZEM, MD JW Goethe University Hospital Frankfurt, Germany FRED POORDAD, MD Texas Liver Institute / University of Texas Health Science Center, USA CHARLES BOUCHER, MD, PHD Erasmus Medical Center, Rotterdam, The Netherlands 3
4 WORKSHOP DESCRIPTION BACKGROUND The entrance of HCV direct acting antivirals into routine clinical practices provides a great opportunity for improved care, but at the same time, substantial challenges for the treating physician. The Workshop on HCV Therapy Advances has been developed to educate treating physicians and researchers, to discuss the latest developments in the field of hepatitis treatment and the promising new treatment possibilities of new direct antivirals that are becoming available. The meeting is intended as a platform for sharing data and discussing the clinical application of these new antivirals. The conference presentations and case discussions presented by international recognized experts in the field are focused on the translation of the latest scientific data and availability of new drugs into daily clinical practice. MEETING OBJECTIVES The objective of this meeting is to create an interactive setting, in which key opinion leaders present and discuss the latest scientific data on clinical management of hepatitis infected patients. LEARNING OBJECTIVES After participating in this activity, the participants will: Have an understanding of the basic concepts of HCV therapy Be updated on the latest developments in the field of HCV antiviral research Have an understanding of the challenges of HCV treatment in different patient populations Have an overview of the advantages and possibilities of new antivirals in HCV therapy Know how to apply direct acting antivirals in clinical practice FORMAT This 1,5 day independent, scientific and educational workshop consists of invited lectures, round-table discussions and clinical case presentations. In order to ascertain an interactive workshop setting, much time is allocated to discussions. UNIQUE MEETING FEATURES The workshop is a unique European platform for clinicians and other professionals working in the field of viral hepatitis, translating new data into new treatment strategies to further improve clinical care The workshop attracts different disciplines involved in the field of HCV therapy The workshop includes the latest data presented at EASL, APASL and AASLD. The workshop stimulates European collaborations and networks The workshop stimulates updates on guidelines and encourages treatment efficiency 4
5 TARGET AUDIENCE Hepatologists Infectious disease doctors Gastroenterologists Other healthcare professionals involved in daily care of hepatitis patients Post-graduate students DEMOGRAPHICS 2013 Clinicians 71% Researchers 0% Marketing person 6% Post -graduate students 0% Other 24% TOTAL number of registrants 100 Returning participants 33,3% New participants 66,7% GEOGRAPHICAL DISTRIBUTION LAST MEETING Australia 1 Russia 1 Austria 1 Saudi Arabia 1 Belgium 14 Spain 3 Finland 4 Sweden 1 France 13 The Netherlands 8 Germany 6 United Kingdom 3 Italy 21 USA 4 Mexico 1 5
6 PROGRAM COMMITTEE STEFAN ZEUZEM, MD JW Goethe University Hospital Frankfurt, Germany FRED POORDAD, MD Texas Liver Institute / University of Texas Health Science Center, USA CHARLES BOUCHER, MD, PHD Erasmus Medical Center, Rotterdam, The Netherlands 6
7 PARTICIPANTS FEEDBACK 2013 PERSONAL BENEFITS This meeting improved my: Agree Neutral Disagree Medical or practical knowledge 100% 0% 0% Care attitudes 71,4% 28,6% 0% Procedural or cognitive skills 66,7% 33,3% 0% Practice behaviour 83,3% 16,7% 0% Patient s clinical outcomes 66,7% 16,7% 16,7 I would recommend this meeting to my colleagues: 86% I plan to attend this meeting again next year: 86% CONTENT Agree Neutral Disagree The content of the meeting met my expectations 85,7% 14,3% 0% Sufficient time allocated for discussion during the meeting 85,7% 14,3% 0% The allocated time per presentation was sufficient 85,7% 14,3% 0% I perceived no commercial bias at the meeting: 100% 7
8 PARTICIPANTS FEEDBACK 2013 LECTURES We are very proud of the evaluation of the invited lectures. Unfortunately Dr. Perno was not able to attend the meeting. FRIDAY, 13 DECEMBER Session 1: DAA s in combination with pegylated interferon and ribavine Boceprevir and telaprevir: efficacy and side effects, what have we learned in 2013 Fred Poordad, MD University of San Antonio Health Science Center, USA Novel DAA s combined with PEG/RIBA Heiner Wedemeyer, MD Hannover Medical School, Germany Content 100% 0% 0% Presentation 100% 0% 0% Content 100% 0% 0% Presentation 100% 0% 0% Session 2: DAA s in clinical development: what are the key A findings Simeprevir overview: From IFN-Containing to IFN-Free Regimens Maria Beaumont, MD Janssen Infectious Diseases Diagnostics BVBA, Belgium Content 100% 0% 0% Presentation 92,9% 7.1% 0% Session 3: Challenging Patient Populations Managing and monitoring of HCCi in the future era of DAA Massimo Colombo, MD University of Milan, Italy The current challenges in treating cirrhotic patients Marc Bourlière, MD Hôpital Saint Joseph, Marseille, France Content 80% 20% 0% Presentation 80% 20% 0% Content 80% 20% 0% Presentation 100% 0% 0% 8
9 SATURDAY, 14 DECEMBER Session 4: Genotype 2&3 and drug resistance Treating HCV genotype 2 & 3 Christophe Sarrazin, MD J.W. Goethe Hospital, Germany Drug resistance findings observed in clinical practice: implications for patient management Carlo Federico Perno, MD, PhD University of Rome Tor Vegata, Italy Latest insights from NUC- containing regimens: what is the best partner molecule? Geoffrey Dusheiko, MD UCL Institute for Liver and Health, Royal Free Hospital, UK Content 85,7% 14,3% 0% Presentation 100% 0% 0% Content Presentation Content 85,7% 14,3% 0% Presentation 85,7% 14,3% 0% Session 5: Interferon Free regimes NUC sparing regimens: where do we stand Stefan Zeuzem, MD J.W. Goethe Hospital, Germany Update: Early investigational trials Peter Ferenci, MD Medical University of Vienna, Austria Content 83,3% 16,7% 0% Presentation 100% 0% 0% Content 50% 50% 0% Presentation 50% 50% 0% 9
10 METRICS 2013 PRE-WORKSHOP COMMUNICATIONS Frequency/ Number Publicity through electronic newsletter 5 x per year / 4121 persons Flyers at other meetings Publicity on conference websites Invitations from industry Endorsements by the following two societies: - Italian Society for Infectious and Tropical Diseases - Italian Association for the Study of the Liver 4 meetings 30 websites yes used their databases for comunications Participants were asked how they heard about this activity. Below are the results: Percentage VE Newsletter 7% Invitation industry 47% VE Website 7% Internet research 13% Flyer at other meetings 0% Other conference agenda 7% Worth of mouth 20 % POST-WORKSHOP COMMUNICATIONS Workshop materials sent to workshop participants + participants previous years. Reviews in Antiviral Therapy & Infectious Diseases Frequency/Number +/ persons 600 hard copy editions and online available on our workshop website ( infectiousdiseasesonline.com/) Publications of presentations by industry 1 10
11 MOST EFFECTIVE ELEMENTS QUOTES The most effective element of this activity was the exchange of clinically relevant managing strategies Interesting discussion of both sessions and oral presentations. Lectures were of high level. Presentations were very informative for us who are not directly involved in the treatment of patients but still provide the analysis for the clinicians. The presentations followed by discussion. Clinical cases presentations and the discussions on this were very interesting and helpful for clinical practice. It s a good way to drive the discussion. 11
12 SUMMARY The Workshop on HCV Therapy Advances Meeting is a unique platform for sharing the most recent data and discussing the clinical application of these new antivirals in an interactive setting. The overall opinion of the meeting was very positive, as can be deducted from the above scores. As the vast majority of the audience consisted of clinicians, we can conclude that the aim of the meeting has been reached. Furthermore, delegates were satisfied with the scientific content of the workshop as well as with the format of the program. The format of this workshop has stimulated a high-level discussion among key opinion leaders and the expert faculty scored an average of 8.6 points for their lectures (on a scale of 1-10, 10 being excellent). Participants were also very pleased with the communication, logistics and content of the meeting. 86 % of the participants would recommend this workshop to their colleagues and more than 86% plans to attend this workshop again next year. Within one week after the meeting, the presentations were made available on the Virology Education website. The success and educational effect of this workshop have underlined the need for continuation. The Program Committee is pleased with the results of the 3 rd Workshop on HCV Therapy Advances and therefore looks forward to organizing the 4 th and 5 th edition of this workshop and welcoming old and new participants. The 4 th edition of the workshop will be held on December 2014 in Paris, France and the 5 th edition will be held in Barcelona, Spain on December
10 5 TH TH WORKSHOP INTERNATIONAL WORKSHOP ON CO-INFECTION NEW ANTIVIRALS IN CLINICAL PRACTICE HIV & HEPATITIS AMSTERDAM, PARIS, FRANCE THE NETHERLANDS 12-13 JUNE 2014 4-5 DECEMBER 2015 MEETING PROSPECTUS
More information12 TH INTERNATIONAL WORKSHOP ON CO-INFECTION HIV & HEPATITIS BERLIN, GERMANY JUNE 2016 MEETING PROSPECTUS www.virology-education.com CONTENT Introduction... 3 Workshop description... 4 Background... 4
More information11 TH INTERNATIONAL WORKSHOP ON CO-INFECTION HIV & HEPATITIS LONDON, UNITED KINGDOM 11-12 JUNE 2015 MEETING PROSPECTUS www.virology-education.com CONTENT Introduction... 3 Workshop description... 4 Background...
More informationunder the aegis of cover picture: Chiostro d Onore University of Milan
under the aegis of cover picture: Chiostro d Onore University of Milan Milan. 2,3 July 2012 Palazzo Visconti MEETING AIM In the last year the therapeutic scenario of chronic hepatitis C has been subverted
More informationHIV FORA: INTEGRATING SCIENCE AND CLINICAL PRACTICE EUROPEAN HIV FORUM: INTEGRASE INHIBITORS MILAN, ITALY 24 OCTOBER 2017 MEETING PROSPECTUS 2017 www.virology-education.com INTRODUCTION & SIGNIFICANCE
More informationThe need for surveillance: How to implement it? Stephanie Popping, MD. Erasmus Medical Center Rotterdam
The need for surveillance: How to implement it? Stephanie Popping, MD. S.Popping@erasmusmc.nl Erasmus Medical Center Rotterdam Era of direct-acting antivirals HCV treatment changed incredibly DAAs are
More informationMEETING PROSPECTUS. HIV CLINICAL FORUM INTEGRASE INHIBITORS DURBAN, SOUTH AFRICA 16 July 2016
MEETING PROSPECTUS HIV CLINICAL FORUM INTEGRASE INHIBITORS DURBAN, SOUTH AFRICA 16 July 2016 VIROLOGY EDUCATION BILTSTRAAT 106 3572 BJ UTRECHT THE NETHERLANDS +31 30 230 7140 INFO@VIROLOGY-EDUCATION.COM
More informationHIV FORA: INTEGRATING SCIENCE AND CLINICAL PRACTICE EUROPEAN HIV FORUM: INTEGRASE INHIBITORS MILAN, ITALY 24 OCTOBER 2017 MEETING PROSPECTUS 2017 www.virology-education.com INTRODUCTION & SIGNIFICANCE
More information1 ST EUROPEAN. NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT.
1 ST EUROPEAN NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT NEEDS ASSESSMENT NEEDS ASSESSMENT Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease affecting 25 % of
More informationMEETING PROSPECTUS 3 RD EUROPEAN WORKSHOP ON WORKSHOP ON HEALTHY LIVING WITH HIV.
3 RD EUROPEAN WORKSHOP ON WORKSHOP ON HEALTHY LIVING WITH HIV BARCELONA, SPAIN, TBC SEPTEMBER 2018 TBC MEETING PROSPECTUS www.hivhealthyliving.com www.expertmedicalevents.com ADVANCING HEALTH GLOBALLY
More informationINTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT.
INTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT INTRODUCTION Liver disease in the setting of HIV is increasingly presenting a major concern
More informationEVALUATION REPORT
International Workshop on NASH Biomarkers 2017 5-6 May 2017 Washington, D.C., EVALUATION REPORT www.expertmedicalevents.com/nashbiomarkers EXECUTIVE SUMMARY INTRODUCTION The 2 nd International Workshop
More information13TH INTERNATIONAL WORKSHOP ON CO-INFECTION HIV & HEPATITIS LISBON, PORTUGAL 24-26 MAY 2017 SPONSORSHIP REQUEST 2017 www.expertmedicalevents.com INTRODUCTION & SIGNIFICANCE BACKGROUND Support our efforts
More informationSPONSORSHIP REQUEST 2017 INTEREST HIV TREATMENT, PATHOGENESIS AND PREVENTION RESEARCH IN RESOURCE-LIMITED SETTINGS.
11 TH INTERNATIONAL WORKSHOP ON HIV TREATMENT, PATHOGENESIS AND PREVENTION RESEARCH IN RESOURCE-LIMITED SETTINGS INTEREST LILONGWE, MALAWI MAY 16-19 2017 SPONSORSHIP REQUEST 2017 www.virology-education.com
More informationAccess to treatment and disease burden
Access to treatment and disease burden Robert Flisiak Department of Infectious Diseases and Hepatology Medical University in Białystok, Poland Moulin de Vernègues, 27-29 August 2015 Disclosures Advisor
More informationINTERNATIONAL CONFERENCE ON MYELOID CELLS AND HIV ITALY 1-3 SEPTEMBER 2018 MEETING PROSPECTUS.
INTERNATIONAL CONFERENCE ON MYELOID CELLS AND HIV ITALY 1-3 SEPTEMBER 2018 MEETING PROSPECTUS ADVANCING HEALTH GLOBALLY THROUGH INNOVATIVE PROGRAMS DESIGNED FOR THE HEALTHCARE PROFESSIONAL 2 TABLE OF CONTENTS
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationINTERNATIONAL WORKSHOP ON HIV & TRANSGENDER PEOPLE MEXICO CITY, MEXICO JULY 2019 MEETING PROSPECTUS.
INTERNATIONAL WORKSHOP ON HIV & TRANSGENDER PEOPLE MEXICO CITY, MEXICO JULY 2019 MEETING PROSPECTUS INTRODUCTION Dear Colleagues, It is our pleasure to announce the organization of the first Workshop focusing
More informationComparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks
Comparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks C Sarrazin, 1 M Buti, 2 C Moreno, 3 M Gschwantler, 4 GR Foster,
More informationMEETING PROSPECTUS. International Workshop on NASH Biomarkers
International Workshop on NASH Biomarkers 2018 18-19 May 2018 Washington, D.C., USA MEETING PROSPECTUS www.expertmedicaleducation.com www.expertmedicalevents.com ADVANCING HEALTH GLOBALLY THROUGH INNOVATIVE
More informationREQUEST FOR SUPPORT 5 TH CENTRAL AND EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND HIV BUDAPEST, HUNGARY OCTOBER 2019 (TBC)
5 TH CENTRAL AND EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND HIV BUDAPEST, HUNGARY 10-11 OCTOBER 2019 (TBC) REQUEST FOR SUPPORT OVERVIEW INTRODUCTION The main objective of the Central and European
More informationBE RECOGNIZED IN THE DEMOLITION INDUSTRY BECOME A MEMBER OF EDA
BE RECOGNIZED IN THE DEMOLITION INDUSTRY BECOME A MEMBER OF EDA What is EDA? 58% of companies noticed GROWTH in their business related to demolition in the past 3 years EDA Industry Report 2016 The European
More informationSurvey Responses to the EUROPEAN COCOA FORUM 2016
Survey Responses to the EUROPEAN COCOA FORUM The survey was sent to all delegates, speakers and moderators who took part in the European Cocoa Forum in Dubrovnik, and aimed at gathering feedback on the
More informationIVHEM 2019 REQUEST FOR SUPPORT INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING.
INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING 2019 AMSTERDAM, THE NETHERLANDS 22-23 NOVEMBER 2019 REQUEST FOR SUPPORT OVERVIEW INTRODUCTION TO The 5th edition of was organized on 6-7 December 2018
More informationInformation Magazine for people with Hepatitis C and HIV. Hepatitis C - Treatment in people with haemophilia, the results to date
Positive News Information Magazine for people with Hepatitis C and HIV Hepatitis C - Treatment in people with haemophilia, the results to date From July 2012 to October 2013, a total of fifteen persons
More information9TH INTERNATIONAL WORKSHOP ON HIV&AGING EAST COAST, USA OCTOBER 2018 MEETING PROSPECTUS.
9TH INTERNATIONAL WORKSHOP ON HIV&AGING EAST COAST, OCTOBER 2018 MEETING PROSPECTUS www.virology-education.com www.expertmedicalevents.com ADVANCING HEALTH GLOBALLY THROUGH INNOVATIVE PROGRAMS DESIGNED
More informationArevir meeting Lize Cuypers
Arevir meeting 2017 Reconstructing the HCV migration history to support public health efforts Lize Cuypers KU Leuven University of Leuven, Department of Microbiology and Immunology, Rega Institute for
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationMEETING PROSPECTUS CHALLENGES & SOLUTIONS INTERNATIONAL WORKSHOP ON HIV ADOLESCENCE CAPE TOWN, SOUTH AFRICA OCTOBER 2018
INTERNATIONAL WORKSHOP ON HIV ADOLESCENCE CHALLENGES & SOLUTIONS CAPE TOWN, SOUTH AFRICA 10-12 OCTOBER 2018 MEETING PROSPECTUS WELCOME Dear Colleague, We are proud to announce the 2nd International Workshop
More informationCuring Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE
Curing Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE AASLD president will discuss current hepatitis B treatment options, to hepatitis C research,
More informationThe Role of Liver Societies in the Global Viral Hepatitis Response
The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationGlobal Patient Survey. Country-Specific Report Belgium
Global Patient Survey Country-Specific Report Belgium HCV Quest Country-Specific Report ABOUT HCV QUEST The biggest barrier I have faced in the fight against viral hepatitis is... no recognition, lack
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationWilhelminenspital, Vienna, Austria; 5 Queen Mary Hospital, University of London, Barts Health, London, UK; 6
Shortening overall treatment to 12 weeks of simeprevir plus PR in treatment-naïve chronic hepatitis C genotype 1 patients: assessment of baseline and Week 2 on-treatment predictors of SVR T Asselah, 1
More informationZimbra jan.klimas@ucd.ie The ISAM Newsletter has arrived From : ISAM Newsletter Sender : ISAM Newsletter Subject : The ISAM Newsletter
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationAngelos Hatzakis. 10th Paris Hepatology Conference
Angelos Hatzakis Professor of Epidemiology and Preventive Medicine Faculty of Medicine National and Kapodistrian University of Athens Co-Chair, Hepatitis B and C Public Policy Association 10th Paris Hepatology
More informationThe Role of Liver Societies in the Global Viral Hepatitis Response
The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationWhat is the extent of gender bias in bioinformatics?
What is the extent of gender bias in bioinformatics? Keith R. Bradnam krbradnam@ucdavis.edu, @kbradnam Genome Center, University of California, Davis Introduction As a male bioinformatician, I was curious
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationSummary Report EU Health Award 2017
EPSA Vaccination Awareness Public Health Campaign 2016 Summary Report EU Health Award 2017 1. Introduction & Case Situation Background With WHO European Vaccine Action Plan 2015-2020 being developed and
More information20 th MCCR WORKSHOP METHODS IN CLINICAL CANCER RESEARCH. Zeist, Netherlands Society Grant Prospectus 2018 JUNE. ecco-org.
20 th MCCR WORKSHOP METHODS IN CLINICAL CANCER RESEARCH Zeist, Netherlands Society Grant Prospectus 2018 16-22 JUNE 2018 ecco-org.eu/workshop TABLE OF CONTENT 1. INTRODUCTION 3 2. EDUCATIONAL FORMAT 5
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationPHOTO. VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe
www.eurordis.org VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe Lucca ( Italy ) March 13-14, 2008 PHOTO www.eurordis.org
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationThe following page contains the final YODA Project review approving this proposal.
The YODA Project Research Proposal Review The following page contains the final YODA Project review approving this proposal. The Yale University Open Data Access (YODA) Project Yale University Center for
More informationEPAG UPDATE. Lenja Wiehe. European Patient Advocacy Groups Manager, EURORDIS
EPAG UPDATE Lenja Wiehe European Patient Advocacy Groups Manager, EURORDIS Patient Centre & Empowerment European Reference Networks (ERNs) created on founding principles of patient-centred care, patient
More informationIntroduction. About the Lupus Academy
Content Introduction Past Activities Barcelona 2012 Buenos Aires 2013 Further Development of the Lupus Academy Berlin 2014 Philippines (APLAR) 2014 Educational support programme Budgets 2 Introduction
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationTREAT-NMD Neuromuscular Network
TREAT-NMD Neuromuscular Network 16 th November 2007 Newsletter No. 21 Welcome to the latest newsletter from the TREAT-NMD network. This edition features a meeting report from last week s patient registry
More informationSPONSORSHIP OPPORTUNITIES
CONFERENCES SPONSORSHIP OPPORTUNITIES 2 nd International Conference on Tropical and Infectious Diseases November 21-22, 2019 Bali, Indonesia our DELEGATE is your CLIENT Our Programme 5+ Keynote Sessions
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationSPONSORSHIP OPPORTUNITIES
CONFERENCES SPONSORSHIP OPPORTUNITIES 5 th World Congress on Epigenetics and Chromosome November 15-16, 2018 Istanbul, Turkey our DELEGATE is your CLIENT Our Programme 5+ Keynote Sessions Our programme
More informationTable Of Content. The European Influenza Surveillance Scheme... 2 Summary... 3 Coordinator, Leader contact and partners Outputs...
Table Of Content The European Influenza Surveillance Scheme... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Institut Pasteur... 6 Health Division... 6 Nphs Communicable Disease Surveillance
More information8 th Congress of ECCO
European Crohn s and Colitis Organisation Vienna Austria 8 th Congress of ECCO Austria Center Vienna February 14-16, 2013 The major educational event in the field of Inflammatory Bowel Diseases in Europe
More informationThe Smokefree Class Competition What is it about?
The Smokefree Class Competition What is it about? a universal smoking prevention programme for pupils aged 11-14 years. The main aims are to delay or prevent the onset of smoking to motivate adolescents
More informationNATIONAL REGISTRIES OF RARE DISEASES IN EUROPE: AN OVERVIEW BY THE EPIRARE PROJECT.
D. Taruscio and L. Vittozzi National Centre for Rare Diseases National Institute of Health Rome, Italy NATIONAL REGISTRIES OF RARE DISEASES IN EUROPE: AN OVERVIEW BY THE EPIRARE PROJECT. ICORD 2014, Ede
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationOptimal Treatment with Boceprevir. Michael Manns
Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency
More informationGlobal Patient Survey. Country-Specific Report China
Global Patient Survey Country-Specific Report China HCV Quest Country-Specific Report ABOUT HCV QUEST Because of the side effects of IFN, I cannot get close to my children 1. Medical insurance/social
More informationManagement of the Diabetic Foot
Pisa International Diabetic Foot Course 2019 Sponsor Information Management of the Diabetic Foot Theory & Practice 4-day course 2-5 October 2019 Pisa, Italy Theory Practice Network www.diabeticfootcourses.org
More informationWorld Connections Committee (WCC) Report
World Connections Committee (WCC) Report 06 Co-Dependents Anonymous Service Conference Countries Where CoDA Exists This report reflects the World Connections Committee (WCC) support of the growth and development
More informationWESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017
WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017 Mary L. Yost 404-520-6652 , LLC 23 Ridge Rd. Beaufort, SC 20097 Copyright Pending 2017 All rights reserved,
More informationInternational Symposium on Quality Assurance for Analytical Methods in Isotope Hydrology
IAEA-CN-119 International Symposium on Quality Assurance for Analytical Methods in Isotope Hydrology 25 27 August 2004 Vienna, Austria Announcement and Call for Papers 1. INTRODUCTION Scarcity of fresh
More informationSupport & Exhibit Prospectus th ANNUAL CONFERENCE International Association for Dance Medicine & Science
27 th ANNUAL CONFERENCE International Association for Dance Medicine & Science Support & Exhibit Prospectus 2017 October 12-15, 2017 Houston, Texas, USA IADMS s W 27 th Annual and Exhibitor Benefit ELCOME
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationTRANSFORMING HCV MANAGEMENT
TRANSFORMING HCV MANAGEMENT Summary of Presentations from the Gilead Sciences (Europe) Symposium, held at the 49 th Annual EASL ILC, London, UK, on 9 th April 2014 Chairperson Graham Foster, 1 Patrick
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationLiver disease in 2017: challenges and opportunities
Liver disease in 2017: challenges and opportunities Dr Matthew Cowan Consultant Gastroenterologist and Hepatologist Surrey and Sussex Healthcare NHS Trust Faculty of Physician Associates 2 nd National
More informationSPONSORSHIP OPPORTUNITIES
CONFERENCES SPONSORSHIP OPPORTUNITIES International Conference on Vaccines and Immune Response June 16-17, 2019 Dubai, UAE our DELEGATE is your CLIENT Our Programme 5+ Keynote Sessions Our programme aims
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationSPONSORSHIP OPPORTUNITIES
CONFERENCES SPONSORSHIP OPPORTUNITIES International Conference on WOMEN S HEALTH, REPRODUCTION AND FERTILITY April 08-09, 2019 Abu Dhabi, UAE our DELEGATE is your CLIENT Our Programme 5+ Keynote Sessions
More informationsquamous cell carcinoma of the head and neck (SCCHN)
EGFR Advisors Network (EAN) meeting for squamous cell carcinoma of the head and neck (SCCHN) Through the patients eyes March 27 28, 2015 InterContinental Hotel Berlin, Germany Chairs to include: Athanassios
More informationNational Women s Health Week Celebration
National Women s Week Celebration Tuesday, May 10, 2016 Lectures Workshops Exhibits Research Posters We invite your company or service to participate! Prentice Women s Hospital 3rd Floor 11:00 a.m. 2:00
More informationSPONSORSHIP CANADIAN GERIATRICS SOCIETY. 38th Annual Scientific Meeting April 19-21, 2018 Hotel Bonaventure, Montreal, QC CONTACT
CANADIAN GERIATRICS SOCIETY 38th Annual Scientific Meeting April 19-21, 2018 Hotel Bonaventure, Montreal, QC SPONSORSHIP 2018 PACKAGE CONTACT Andrea Smith, Conference Manager events@secretariatcentral.com
More informationThe Academy for Clinical Debates & Controversies in Medicine C-HEP BARCELONA SPAIN MAY 19-22, 2011 ANNOUNCEMENT
The Academy for Clinical Debates & Controversies in Medicine C-HEP 1 st World Congress on CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Second ANNOUNCEMENT Last update: March 9, 2011 www.comtecmed.com/chep
More informationSupport & Exhibit Prospectus th ANNUAL CONFERENCE International Association for Dance Medicine & Science
IADMS s 28 th and Exhibitor Benefit 28 th ANNUAL CONFERENCE International Association for Dance Medicine & Science Support & Exhibit Prospectus 2018 October 25-28, 2018 Helsinki, Finland IADMS s W 28 th
More informationPresident s Message November 16, 2011
President s Message November 16, 2011 Dear House of Delegate s (HOD) Members: I am sending this additional report as there was insufficient space in Contact International (CI). The Executive Council (EC)
More informationVosevi (sofosbuvir/velpatasvir/voxilaprevir)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationIndustry Partners. Information and Benefits
Industry Partners Information and Benefits 1968 to today Founded in 1968, the EACR is Europe s professional membership association for those working and studying in cancer research, with over 10,000 members
More informationPegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013
PegIntron (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1143DFR / Published May 2013 Executive Summary PegIntron (peginterferon alfa-2b) Key Metrics in the Major Pharmaceutical Markets 2012
More informationHPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION
How-To Guide for Hosting Town Hall Meetings Town hall meetings can be an effective approach to educating a community about a particular issue, such as HPV and cervical cancer, while also engaging constituents
More informationrare diseases research through National Plans and Strategies
Recommendations to support rare diseases research through National Plans and Strategies Dr Domenica Taruscio EUROPLAN Coordinator Director of the Italian Centre for Rare Diseases, Italian National Institute
More informationESMO FELLOWSHIP PROGRAMME & LEADERS GENERATION PROGRAMME
ESMO FELLOWSHIP PROGRAMME & LEADERS GENERATION PROGRAMME Christoph Zielinski Chair of the ESMO Fellowship & Award Committee esmo.org ESMO FELLOWSHIP PROGRAMME Exclusive to ESMO members under 40 years old
More informationDirect-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
DOI 10.1007/s10620-011-1604-3 ORIGINAL ARTICLE Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use Paul J. Gaglio Noah Moss Camille McGaw John Reinus Received: 15 December 2010
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationThe Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy
280 POSITION PAPER : BELGIAN WORKING GROUP FOR HEPATITIS C The Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy P. Stärkel 1, D. Vandijck 2,3, W. Laleman 4,
More informationEuropean Patients Academy on Therapeutic Innovation
European Patients Academy on Therapeutic Innovation http://www.patientsacademy.eu info@patientsacademy.eu The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under
More informationPractical experience in implementing surveillance of antiviral resistance in several European countries in accordance with personal data regulation
Practical experience in implementing surveillance of antiviral resistance in several European countries in accordance with personal data regulation Katja Deterding Medizinische Hochschule Hannover Antiviral
More informationTable Of Content. Page 1/8
Table Of Content 22nd Conference: Changing perceptions, practice and policy... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D04-00 - Programme and book of abstracts (EN)...
More information4 th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 1. IAS 2007 Evaluation: Delegate Survey
4 th IAS Conference on HIV Pathogenesis, Treatment and Prevention Appendices 1. IAS 2007 Evaluation: Delegate Survey 2. Report of the longer-term impact of the 3 rd IAS Conference on HIV Pathogenesis,
More informationCase Study: Physician and Patient-Facing Medical Education APPs. Sandeep Pulim, MD Chief Medical Information Officer
Case Study: Physician and Patient-Facing Medical Education APPs Sandeep Pulim, MD Chief Medical Information Officer Quality IME Collaborating for Patient Care Commercial Supporter Medical Education Provider
More informationSPONSORSHIP OPPORTUNITIES
CONFERENCES SPONSORSHIP OPPORTUNITIES World congress on Polycystic ovarian Syndrome and Fertility October 18-19, 2018 Abu Dhabi, UAE our DELEGATE is your CLIENT Our Programme 5+ Keynote Sessions PCOS2018
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationFRIDAY, MARCH 9 SUNDAY, MARCH
33RD A N N U A L New Treatments in Chronic Liver Disease FRIDAY, MARCH 9 SUNDAY, MARCH 11, 2018 Pre-Conference: Friday, March 9, 2018 Main Conference: Saturday, March 10-11, 2018 Estancia La Jolla Course
More information